Janus Henderson Discloses 6% Stake in Compass Therapeutics
Ticker: JHG · Form: SC 13G · Filed: Feb 1, 2024 · CIK: 1274173
| Field | Detail |
|---|---|
| Company | Janus Henderson Group PLC (JHG) |
| Form Type | SC 13G |
| Filed Date | Feb 1, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, insider-buy, biotech, investment-advisor
TL;DR
**Janus Henderson just bought 6% of Compass Therapeutics, signaling institutional confidence.**
AI Summary
Janus Henderson Group plc, a major investment advisor, reported on February 1, 2024, that it holds 6.00% of the common stock of Compass Therapeutics, Inc. This significant stake, established as of January 22, 2024, indicates Janus Henderson's belief in Compass Therapeutics' future prospects. For current or prospective Compass Therapeutics shareholders, this filing signals that a large institutional investor sees value in the company, potentially boosting investor confidence and stock stability.
Why It Matters
This filing shows a major institutional investor, Janus Henderson, has taken a significant position in Compass Therapeutics, which can be seen as a vote of confidence in the company's future.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investment, which generally reduces risk by providing stability and validation.
Analyst Insight
A smart investor would view this as a positive signal, potentially indicating a deeper dive into Compass Therapeutics' fundamentals and considering it for their portfolio, given the institutional validation.
Key Numbers
- 6.00% — Ownership Stake (Percentage of Compass Therapeutics, Inc. common stock owned by Janus Henderson Group plc.)
Key Players & Entities
- Janus Henderson Group plc (company) — the reporting person and investment advisor
- Compass Therapeutics, Inc. (company) — the subject company whose stock was acquired
- 6.00% (dollar_amount) — the percentage of Compass Therapeutics common stock owned by Janus Henderson
- January 22, 2024 (date) — the date of the event requiring the filing
- February 1, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- Other institutional investors may increase their positions in Compass Therapeutics, Inc. following Janus Henderson's disclosed stake. (Compass Therapeutics, Inc.) — medium confidence, target: Within 6 months
FAQ
What is the name of the entity that filed this SC 13G?
The entity that filed this SC 13G is Janus Henderson Group plc, as stated in the 'FILED BY' section and the cover page.
What percentage of Compass Therapeutics, Inc. common stock does Janus Henderson Group plc now own?
Janus Henderson Group plc owns 6.00% of Compass Therapeutics, Inc. common stock, as explicitly stated in the filing summary and the 'JANUS HENDERSON GROUP PLC OWNS 6.00% OF COMPASS THERAPEUTICS, INC.' section.
What is the CUSIP number for Compass Therapeutics, Inc. common stock mentioned in the filing?
The CUSIP number for Compass Therapeutics, Inc. common stock is 20454B104, as listed under 'CUSIP Number' on the cover page.
When was the event that triggered the requirement for this SC 13G filing?
The date of the event which required the filing of this statement was January 22, 2024, as indicated under 'Date of Event Which Requires Filing of this Statement'.
Under which rule(s) of the Securities Exchange Act of 1934 was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b) and Rule 13d-1(c), as indicated by the checked boxes on the cover page.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 1, 2024 regarding JANUS HENDERSON GROUP PLC (JHG).